Patients with relapsed, refractory or advanced stage B non-Hodgkin lymphoma (NHL) continue to have a dismal prognosis. This review summarises current and novel cellular and immunotherapy for these high-risk populations, including haematopoietic stem cell transplant, bispecific antibodies, viral-derived cytotoxic T cells, chimeric antigen receptor (CAR) T cells, and natural killer (NK) cell therapy, as discussed at the 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma on September 26th–29th 2018 in Rotterdam, the Netherlands, and explores the future of NK/CAR NK therapies.
Bibliographical noteFunding Information:
Supported in part by grants from Pediatric Cancer Research Foundation (MSC), St. Baldrick’s Foundation (MSC), New York Medical College School of Medicine Translational Science Institute Children Health Translational Research Award (YC), National Cancer Institute (MSC) (1R13CA232383-01) and National Heart, Lung and Blood Institute (MSC) (1R13CA232383-01).
- B-cell non-Hodgkin lymphoma
- IL-15 superagonist
- cellular immunotherapy
- chimeric antigen receptor
- stem cell transplantation